Adamas Pharmaceuticals Statistics
Share Statistics
Adamas Pharmaceuticals has 0
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.65 and the forward
PE ratio is null.
Adamas Pharmaceuticals's PEG ratio is
0.05.
| PE Ratio | -2.65 |
| Forward PE | n/a |
| PS Ratio | 2.05 |
| Forward PS | n/a |
| PB Ratio | -3.05 |
| P/FCF Ratio | -3 |
| PEG Ratio | 0.05 |
Financial Ratio HistoryEnterprise Valuation
Adamas Pharmaceuticals has an Enterprise Value (EV) of 210.58M.
| EV / Sales | 2.83 |
| EV / EBITDA | -4.86 |
| EV / EBIT | -4.15 |
| EV / FCF | -4.15 |
Financial Position
The company has a current ratio of 3.2,
with a Debt / Equity ratio of -2.6.
| Current Ratio | 3.2 |
| Quick Ratio | 3 |
| Debt / Equity | -2.6 |
| Debt / EBITDA | -3 |
| Debt / FCF | -2.56 |
| Interest Coverage | -3.34 |
Financial Efficiency
Return on Equity is 114.86% and Return on Invested Capital is -55.21%.
| Return on Equity | 114.86% |
| Return on Assets | -47.82% |
| Return on Invested Capital | -55.21% |
| Revenue Per Employee | $539,572.46 |
| Profits Per Employee | $-415,963.77 |
| Employee Count | 138 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 2.82, so Adamas Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 2.82 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 1,338,689 |
Income Statement
In the last 12 months, Adamas Pharmaceuticals had revenue of 74.46M
and earned -57.4M
in profits. Earnings per share was -1.63.
| Revenue | 74.46M |
| Gross Profit | 72.42M |
| Operating Income | -44.16M |
| Net Income | -57.4M |
| EBITDA | -43.31M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.63 |
Full Income StatementBalance Sheet
The company has 71.66M in cash and 129.96M in
debt, giving a net cash position of -58.3M.
| Cash & Cash Equivalents | 71.66M |
| Total Debt | 129.96M |
| Net Cash | -58.3M |
| Retained Earnings | -505.29M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -50.71M
and capital expenditures 0, giving a free cash flow of -50.71M.
| Operating Cash Flow | -50.71M |
| Capital Expenditures | n/a |
| Free Cash Flow | -50.71M |
| FCF Per Share | -1.44 |
Full Cash Flow StatementMargins
Gross margin is 97.26%, with operating and profit margins of -59.31% and -77.09%.
| Gross Margin | 97.26% |
| Operating Margin | -59.31% |
| Pretax Margin | -77.09% |
| Profit Margin | -77.09% |
| EBITDA Margin | -58.17% |
| EBIT Margin | -59.31% |
| FCF Margin | -68.1% |
